SML2206
SKA-121
≥98% (HPLC)
别名:
5-Methylnaphth[2,1-d]oxazol-2-amine, 5-Methylnaphtho[2,1-d]oxazol-2-amine, SKA 121, SKA121
登录 查看组织和合同定价。
选择规格
变更视图
关于此项目
Assay:
≥98% (HPLC)
Form:
powder
assay
≥98% (HPLC)
form
powder
color
brown to dark gray
solubility
DMSO: 2 mg/mL, clear
storage temp.
2-8°C
SMILES string
CC(C1=C2C=CC=C1)=CC3=C2OC(N)=N3
InChI
1S/C12H10N2O/c1-7-6-10-11(15-12(13)14-10)9-5-3-2-4-8(7)9/h2-6H,1H3,(H2,13,14)
InChI key
JEGUERWMMMQFJV-UHFFFAOYSA-N
Biochem/physiol Actions
KCa3.1 subtype-selective Ca2+-activated K+ channel activator with in vivo arterial blood pressure-lowering efficacy. More potent and selective than SKA-31.
SKA-121 is a KCa3.1 (IKCa1, IK1, KCa4, SKCa4, SK4) subtype-selective small conductance Ca2+-activated K+ channel (SK channel) positive-gating modulator (EC50 = 109 nM/KCa3.1 vs. 8.7 μM/KCa2.1, 6.8 μM/KCa2.2, 4.4 μM/KCa2.3) with 200- to 400-fold selectivity over CaV1.2 as well as representative KVs (KV1.3, KV2.1, KV3.1, and KV11.1) and NaV (NaV1.2, NaV1.4, NaV1.5, and NaV1.7) channels. When applied in vivo, SKA-121 significantly lowers mean arterial blood pressure in wild-type, but not KCa3.1(-/-), normotensive and hypertensive mice (100 mg/kg i.p.). SKA-121 is a more potent and selective KCa3.1 activator than SKA-31 (EC50 = 260 nM/KCa3.1, 2.9 μM/KCa2.1, 1.9 μM/KCa2.2, 2.9 μM/KCa2.3).
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable